Merix Bioscience has launched its first corporate-sponsored clinical trial, one that focuses on a possible treatment for kidney cancer.
The study is underway at five sites in the United States and Canada.
More than 30,000 people are afflicted with kidney cancer each year.
“We have developed a cancer vaccine that harnesses the ability of an individual’s immune system to fight disease,” said Clint Dederick, Jr., the chairman, president and CEO of Merix, in a statement. “We strongly believe that by utilizing an individual patient’s tumor antigens to create a personalized vaccine, we can induce the broadest possible immune response and maximize the anti-tumor responses.”
Early-stage clinical studies have already been conducted at Duke University.
Merix said it expects to receive first results of the trial “early next year”.